press-release · recognition
Annate Bitherapeutics has been awarded a $400K SBIR Phase I grant from the National Cancer Institute to advance ANN-01M, the company’s lead bispecific antibody program for relapsed/refractory multiple myeloma. Read More ›
press-release · recognition · research
The University of Georgia’s Hajduk Lab has been awarded a $250,000 International Myeloma Society and Paula and Rodger Riney Foundation Translational Research Grant supporting multiple myeloma research connected to Annate’s platform. Read More ›
press-release · recognition · events
Annate Bitherapeutics won at the 2026 GIPA Startup Awards, recognizing Georgia startups that use intellectual property as a strategic business asset. Read More ›
press-release · events · recognition
Annate Bitherapeutics CEO Eric DeJesus, PhD, joined Georgia Life Sciences in Washington, DC, for the Council of State Bioscience Associations Fly-In to advocate for policies that support innovation, patients, and U.S. biotech leadership. Read More ›
press-release · recognition
UGA Research spotlighted Annate Bitherapeutics in a feature on the personal story and scientific mission driving the company’s work to develop new cancer therapies. Read More ›